Cargando…

Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients—A pilot study

The Roux-en-Y gastric bypass (RYGB) remains the most effective treatment for morbidly obese patients to lower body weight and improve glycemic control. There is recent evidence that the mycobiome (fungal microbiome) can aggravate disease severity in a number of diseases including inflammatory bowel...

Descripción completa

Detalles Bibliográficos
Autores principales: Steinert, Robert E., Rehman, Ateequr, Souto Lima, Everton Job, Agamennone, Valeria, Schuren, Frank H. J., Gero, Daniel, Schreiner, Phillip, Vonlanthen, René, Ismaeil, Aiman, Tzafos, Stefanos, Hosa, Hanna, Vetter, Diana, Misselwitz, Benjamin, Bueter, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394366/
https://www.ncbi.nlm.nih.gov/pubmed/32735609
http://dx.doi.org/10.1371/journal.pone.0236936
_version_ 1783565216190038016
author Steinert, Robert E.
Rehman, Ateequr
Souto Lima, Everton Job
Agamennone, Valeria
Schuren, Frank H. J.
Gero, Daniel
Schreiner, Phillip
Vonlanthen, René
Ismaeil, Aiman
Tzafos, Stefanos
Hosa, Hanna
Vetter, Diana
Misselwitz, Benjamin
Bueter, Marco
author_facet Steinert, Robert E.
Rehman, Ateequr
Souto Lima, Everton Job
Agamennone, Valeria
Schuren, Frank H. J.
Gero, Daniel
Schreiner, Phillip
Vonlanthen, René
Ismaeil, Aiman
Tzafos, Stefanos
Hosa, Hanna
Vetter, Diana
Misselwitz, Benjamin
Bueter, Marco
author_sort Steinert, Robert E.
collection PubMed
description The Roux-en-Y gastric bypass (RYGB) remains the most effective treatment for morbidly obese patients to lower body weight and improve glycemic control. There is recent evidence that the mycobiome (fungal microbiome) can aggravate disease severity in a number of diseases including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and hepatitis; moreover, a dysbiotic fungal microbiota has been reported in the obese. We characterized fungal and bacterial microbial composition in fecal samples of 16 morbidly obese patients before and three months after RYGB surgery and compared with nine healthy controls. We found that RYGB surgery induced a clear alteration in structure and composition of the gut fungal and bacterial microbiota. Beta diversity analysis revealed significant differences in bacterial microbiota between obese patients before surgery and healthy controls (P < 0.005) and a significant, unidirectional shift in RYGB patients after surgery (P < 0.001 vs. before surgery). In contrast, there was no significant difference in fungal microbiota between groups but individually specific changes after RYGB surgery. Interestingly, RYGB surgery induced a significant reduction in fungal alpha diversity namely Chao1, Sobs, and Shannon diversity index (P<0.05, respectively) which contrasts the trend for uniform changes in bacteria towards increased richness and diversity post-surgery. We did not observe any inter-kingdom relations in RYGB patients but in the healthy control cohort and there were several correlations between fungi and bacteria and clinical parameters (P<0.05, respectively) that warrant further research. Our study identifies changes in intestinal fungal communities in RYGB patients that are distinct to changes in the bacterial microbiota.
format Online
Article
Text
id pubmed-7394366
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-73943662020-08-07 Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients—A pilot study Steinert, Robert E. Rehman, Ateequr Souto Lima, Everton Job Agamennone, Valeria Schuren, Frank H. J. Gero, Daniel Schreiner, Phillip Vonlanthen, René Ismaeil, Aiman Tzafos, Stefanos Hosa, Hanna Vetter, Diana Misselwitz, Benjamin Bueter, Marco PLoS One Research Article The Roux-en-Y gastric bypass (RYGB) remains the most effective treatment for morbidly obese patients to lower body weight and improve glycemic control. There is recent evidence that the mycobiome (fungal microbiome) can aggravate disease severity in a number of diseases including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and hepatitis; moreover, a dysbiotic fungal microbiota has been reported in the obese. We characterized fungal and bacterial microbial composition in fecal samples of 16 morbidly obese patients before and three months after RYGB surgery and compared with nine healthy controls. We found that RYGB surgery induced a clear alteration in structure and composition of the gut fungal and bacterial microbiota. Beta diversity analysis revealed significant differences in bacterial microbiota between obese patients before surgery and healthy controls (P < 0.005) and a significant, unidirectional shift in RYGB patients after surgery (P < 0.001 vs. before surgery). In contrast, there was no significant difference in fungal microbiota between groups but individually specific changes after RYGB surgery. Interestingly, RYGB surgery induced a significant reduction in fungal alpha diversity namely Chao1, Sobs, and Shannon diversity index (P<0.05, respectively) which contrasts the trend for uniform changes in bacteria towards increased richness and diversity post-surgery. We did not observe any inter-kingdom relations in RYGB patients but in the healthy control cohort and there were several correlations between fungi and bacteria and clinical parameters (P<0.05, respectively) that warrant further research. Our study identifies changes in intestinal fungal communities in RYGB patients that are distinct to changes in the bacterial microbiota. Public Library of Science 2020-07-31 /pmc/articles/PMC7394366/ /pubmed/32735609 http://dx.doi.org/10.1371/journal.pone.0236936 Text en © 2020 Steinert et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Steinert, Robert E.
Rehman, Ateequr
Souto Lima, Everton Job
Agamennone, Valeria
Schuren, Frank H. J.
Gero, Daniel
Schreiner, Phillip
Vonlanthen, René
Ismaeil, Aiman
Tzafos, Stefanos
Hosa, Hanna
Vetter, Diana
Misselwitz, Benjamin
Bueter, Marco
Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients—A pilot study
title Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients—A pilot study
title_full Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients—A pilot study
title_fullStr Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients—A pilot study
title_full_unstemmed Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients—A pilot study
title_short Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients—A pilot study
title_sort roux-en-y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients—a pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394366/
https://www.ncbi.nlm.nih.gov/pubmed/32735609
http://dx.doi.org/10.1371/journal.pone.0236936
work_keys_str_mv AT steinertroberte rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT rehmanateequr rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT soutolimaevertonjob rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT agamennonevaleria rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT schurenfrankhj rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT gerodaniel rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT schreinerphillip rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT vonlanthenrene rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT ismaeilaiman rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT tzafosstefanos rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT hosahanna rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT vetterdiana rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT misselwitzbenjamin rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy
AT buetermarco rouxenygastricbypasssurgerychangesfungalandbacterialmicrobiotainmorbidlyobesepatientsapilotstudy